Your browser doesn't support javascript.
loading
Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis.
Blue, Brandon J; Brazauskas, Ruta; Chen, Karen; Patel, Jinalben; Zeidan, Amer M; Steinberg, Amir; Ballen, Karen; Kwok, Janette; Rotz, Seth J; Perez, Miguel Angel Diaz; Kelkar, Amar H; Ganguly, Siddhartha; Wingard, John R; Lad, Deepesh; Sharma, Akshay; Badawy, Sherif M; Lazarus, Hillard M; Hashem, Hasan; Szwajcer, David; Knight, Jennifer M; Bhatt, Neel S; Page, Kristin; Beattie, Sara; Arai, Yasuyuki; Liu, Hongtao; Arnold, Staci D; Freytes, César O; Abid, Muhammad Bilal; Beitinjaneh, Amer; Farhadfar, Nosha; Wirk, Baldeep; Winestone, Lena E; Agrawal, Vaibhav; Preussler, Jaime M; Seo, Sachiko; Hashmi, Shahrukh; Lehmann, Leslie; Wood, William A; Rangarajan, Hemalatha G; Saber, Wael; Majhail, Navneet S.
Afiliación
  • Blue BJ; Moffitt Cancer Center, Tampa, FL. Electronic address: Brandon.Blue@moffitt.org.
  • Brazauskas R; CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI.
  • Chen K; CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
  • Patel J; CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
  • Zeidan AM; Section of Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT.
  • Steinberg A; Westchester Medical Center, Valhalla, NY.
  • Ballen K; Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA.
  • Kwok J; Division of Transplantation and Immunogenetics, Department of Pathology, Queen Mary Hospital, Hong Kong.
  • Rotz SJ; Department of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Cleveland Clinic, Cleveland, OH.
  • Perez MAD; Department of Hematology/Oncology, Hospital Infantil Universitario Niño Jesus, Madrid, Spain.
  • Kelkar AH; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Ganguly S; Houston Methodist Hospital and Neal Cancer Center, Houston, TX.
  • Wingard JR; Division of Hematology & Oncology, Department of Medicine, University of Florida, Gainesville, FL.
  • Lad D; Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, India.
  • Sharma A; Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN.
  • Badawy SM; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL; Division of Hematology, Oncology, and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.
  • Lazarus HM; University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH.
  • Hashem H; Division of Pediatric Hematology/Oncology and Bone marrow Transplantation, King Hussein Cancer Center, Amman, Jordan.
  • Szwajcer D; Cancer Care Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Knight JM; Section of BMT & Cellular Therapies; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee, WI; Department of Microbiology & Immunology, Medical College o
  • Bhatt NS; University of Washington School of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
  • Page K; CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI.
  • Beattie S; Department of Psychosocial Oncology and Rehabilitation, Tom Baker Cancer Centre, Calgary, Canada; Department of Oncology, University of Calgary, Canada.
  • Arai Y; Kyoto University Hospital, Kyoto University, Kyoto, Japan.
  • Liu H; Section of Hematology/Oncology, University of Chicago Medicine, Chicago, IL.
  • Arnold SD; Aflac Cancer and Blood Disorder Center Children's Healthcare of Atlanta Emory University, Atlanta, GA.
  • Freytes CO; University of Texas Health Science Center at San Antonio, San Antonio, TX.
  • Abid MB; Divisions of Hematology/Oncology & Infectious Diseases, BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI.
  • Beitinjaneh A; Division of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, FL.
  • Farhadfar N; Division of Hematology/Oncology, University of Florida College of Medicine, Gainesville, FL.
  • Wirk B; Bone Marrow Transplant Program, Penn State Cancer Institute, Hershey, PA.
  • Winestone LE; Division of Allergy, Immunology, and Blood & Marrow Transplant, University of California San Francisco Benioff Children's Hospitals, San Francisco, CA.
  • Agrawal V; Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
  • Preussler JM; CIBMTR® (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, MN.
  • Seo S; Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.
  • Hashmi S; Department of Medicine, Sheikh Shakhbout Medical City, Abu Dhabi, UAE; Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN; College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, UAE.
  • Lehmann L; Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, MA.
  • Wood WA; Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, NC.
  • Rangarajan HG; Department of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Nationwide Children's hospital, Columbus, OH.
  • Saber W; CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
  • Majhail NS; Sarah Cannon Transplant and Cellular Therapy Network, Nashville, TN.
Transplant Cell Ther ; 29(11): 709.e1-709.e11, 2023 Nov.
Article en En | MEDLINE | ID: mdl-37482244
ABSTRACT
Racial/ethnic minorities have demonstrated worse survival after allogeneic hematopoietic cell transplantation (HCT) compared to whites. Whether the racial disparity in HCT outcomes persists in long-term survivors and possibly may be even exacerbated in this population, which frequently transitions back from the transplant center to their local healthcare providers, is unknown. In the current study, we compared long-term outcomes among 1-year allogeneic HCT survivors by race/ethnicity and socioeconomic status (SES). The Center for International Blood and Marrow Transplant Research database was used to identify 5473 patients with acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, or myelodysplastic syndromes who underwent their first allogeneic HCT between 2007 and 2017 and were alive and in remission for at least 1 year after transplantation. The study was restricted to patients who underwent HCT in the United States. SES was defined using patient neighborhood poverty level estimated from the recipient's ZIP code of residence; a ZIP code with ≥20% of persons below the federal poverty level was considered a high poverty area. The primary outcome was to evaluate the associations of race/ethnicity and neighborhood poverty level with overall survival (OS), relapse, and nonrelapse mortality (NRM). Cox regression models were used to determine associations of ethnicity/race and SES with OS, relapse, and NRM. Standardized mortality ratios were calculated to compare mortality rates of the study patients and their general population peers matched on race/ethnicity, age, and sex. The study cohort was predominately non-Hispanic white (n = 4385) and also included non-Hispanic black (n = 338), Hispanic (n = 516), and Asian (n = 234) patients. Overall, 729 patients (13%) resided in high-poverty areas. Significantly larger proportions of non-Hispanic black (37%) and Hispanic (26%) patients lived in high-poverty areas compared to non-Hispanic whites (10%) and Asians (10%) (P < .01). Multivariable analysis revealed no significant associations between OS, PFS, relapse, or NRM and race/ethnicity or poverty level when adjusted for patient-, disease- and transplantation-related covariates. Our retrospective cohort registry study shows that among adult allogeneic HCT recipients who survived at least 1 year in remission, there were no associations between race/ethnicity, neighborhood poverty level, and long-term outcomes.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Disparidades Socioeconómicas en Salud Límite: Adult / Humans País/Región como asunto: America do norte Idioma: En Revista: Transplant Cell Ther Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Disparidades Socioeconómicas en Salud Límite: Adult / Humans País/Región como asunto: America do norte Idioma: En Revista: Transplant Cell Ther Año: 2023 Tipo del documento: Article